We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The World Business Council for Sustainable Development (WBCSD), in collaboration with leading pharmaceutical companies and ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analy ...

Rather than NCS, the GSK trials used a different co-primary ... commercial chief at Regeneron, said during a conference call last month. The three biologics work in different ways.

GSK and Vertex Pharmaceuticals ... s actual appearance on a panel discussion about women’s health at the SXSW conference over the weekend. A detailed post from Regeneron lists several areas ...